Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Donald Trump has launched a new war, this time against pharmaceutical companies. He has signed an executive order to reduce ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

The best metric is not weight, but a particularly toxic kind of fat.

During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...